Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 2/20 | 0.52 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | TRIM24 | O15164 | 3/20 | 0.51 |
| ▸ | DRD1 | P21728 | 2/20 | 0.46 |
| ▸ | DRD5 | P21918 | 2/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KYAT1 | Q16773 | 1/20 | 0.44 |
| ▸ | KYAT3 | Q6YP21 | 1/20 | 0.44 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.44 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15964822 | 0.90 | LMNA (0.49) | CYP11B1CYP11B2CYP1A2LMNATRIM24 | |
| SCHEMBL6073478 | 0.87 | TRIM24 (0.64) | CYP11B1CYP11B2CYP1A2LMNATRIM24 | |
| SCHEMBL6074566 | 0.85 | HTT (0.53) | CYP1A2LMNADRD1DRD5DRD2 | |
| SCHEMBL6073997 | 0.83 | BRD4 (0.45) | CYP11B1CYP11B2CYP1A2LMNATRIM24 | |
| SCHEMBL6603783 | 0.80 | DRD1 (0.46) | LMNADRD1DRD5DRD2DRD3 | |
| SCHEMBL11064135 | 0.79 | — | — | |
| SCHEMBL20284777 | 0.78 | CHRM1 (0.48) | DRD2DRD3POLBKYAT1KYAT3 | |
| SCHEMBL885383 | 0.78 | DRD2 (0.42) | LMNADRD1DRD5DRD2DRD3 | |
| SCHEMBL12059735 | 0.78 | LMNA (0.56) | CYP11B1CYP11B2CYP1A2LMNATRIM24 | |
| SCHEMBL10890659 | 0.77 | TRIM24 (0.46) | CYP11B1CYP11B2CYP1A2TRIM24DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114853642-A | Synthesis method for directly alkylating benzyl position of aromatic compound | 西湖大学 | 2022-08-05 | — | — | CN | disclosed |
| US-8524738-B2 | Quinolinones and quinoxalinones as antibacterial composition | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-09-03 | — | — | US | disclosed |
| US-8329694-B2 | Quinoxalinones as antibacterial composition | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-12-11 | — | — | US | disclosed |
| US-8329694-B2 | Quinoxalinones as antibacterial composition | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-12-11 | — | — | US | disclosed |
| US-20120214990-A1 | QUINOLINONES AND QUINOXALINONES AS ANTIBACTERIAL COMPOSITION | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-08-23 | — | — | US | disclosed |
| US-20100168418-A1 | NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2010-07-01 | — | — | US | disclosed |
| US-20100168418-A1 | NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2010-07-01 | — | — | US | disclosed |
| US-7119207-B2 | Benzoamide piperidine containing compounds and related compounds | PFIZER INC (US) | 2006-10-10 | — | — | US | disclosed |
| EP-1175417-B1 | SUBSTITUTED BENZOLACTAM COMPOUNDS | PFIZER PROD INC (US) | 2004-01-07 | — | — | EP | disclosed |
| US-20030105124-A1 | Substituted benzolactam compounds | SOBOLOV-JAYNES SUSAN BETH (US) | 2003-06-05 | — | — | US | disclosed |
| EP-1272484-A2 | BENZOAMIDE PIPERIDINE COMPOUNDS AS SUBSTANCE P ANTAGONISTS | Pfizer Products Inc. (US) | 2003-01-08 | — | — | EP | disclosed |
| US-20020052503-A1 | Substituted benzolactam compounds as substance p antagonists | WAKABAYASHI HIROAKI (JP) | 2002-05-02 | — | — | US | disclosed |
| EP-1175417-A1 | SUBSTITUTED BENZOLACTAM COMPOUNDS | Pfizer Products Inc. (US) | 2002-01-30 | — | — | EP | disclosed |
| WO-2001077100-A2 | BENZOAMIDE PIPERIDINE COMPOUNDS AS SUBSTANCE P ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2001-10-18 | — | — | WO | disclosed |
| US-6288225-B1 | Substituted benzolactam compounds as substance P antagonists | PFIZER INC | 2001-09-11 | — | — | US | disclosed |
| EP-0840732-B1 | SUBSTITUTED BENZOLACTAM COMPOUNDS AS SUBSTANCE P ANTAGONISTS | PFIZER (US) | 2001-03-07 | — | — | EP | disclosed |
| US-6180647-B1 | GASTROINTESTINAL DISORDERS; NERVOUS SYSTEM DISORDERS | PFIZER INC. | 2001-01-30 | — | — | US | disclosed |
| WO-2000068224-A1 | SUBSTITUTED BENZOLACTAM COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2000-11-16 | — | — | WO | disclosed |
| EP-0840732-A1 | SUBSTITUTED BENZOLACTAM COMPOUNDS AS SUBSTANCE P ANTAGONISTS | PFIZER INC. (US) | 1998-05-13 | — | — | EP | disclosed |
| WO-1997003066-A1 | SUBSTITUTED BENZOLACTAM COMPOUNDS AS SUBSTANCE P ANTAGONISTS | PFIZER PHARMACEUTICALS INC. (JP) | 1997-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105124-A1 | Substituted benzolactam compounds | NPY1R, HAX1, CBR1 | CYP11B1 510/4885CYP11B2 487/4885CYP1A2 197/4885 |
| US-20100168418-A1 | NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF | ROS1, NOX1, ARG1 | CYP11B1 829/4885CYP11B2 828/4885CYP1A2 1260/4885 |
| US-20020052503-A1 | Substituted benzolactam compounds as substance p antagonists | NPY1R, OPRM1, OPRL1 | CYP11B1 1239/4885CYP11B2 1586/4885CYP1A2 1021/4885 |
| US-20120214990-A1 | QUINOLINONES AND QUINOXALINONES AS ANTIBACTERIAL COMPOSITION | NQO2, ASNS, NDUFS1 | CYP11B1 3403/4885CYP11B2 3591/4885CYP1A2 1206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.